Regarding the prevention of blood coagulation, most research in the past decade has been focused on thrombin inhibition.
Regarding the prevention of blood coagulation, most research in the past decade has been focused on thrombin inhibition. 1, 2) More recently, inhibition of factor Xa (FXa), which is directly responsible for prothrombin activation, has emerged as an attractive target.
FXa, which converts prothrombin to thrombin, holds a central position in the coagulation cascade.
3) One molecule of FXa generates over 100 molecules of thrombin. Therefore, inhibition of FXa may be more effective than inhibition of thrombin for the prevention of blood coagulation. 4, 5) In addition, a recent study by Harker et al. 6 ) in a balloon model of thrombosis showed that FXa inhibitors might have less bleeding risk than thrombin inhibitors. 7) Most of the nonpeptide FXa inhibitors reported in the literature are dibasic compounds. Nagahara et al. 8, 9) have reported synthesis and evaluation of a series of bis(amidino)-derivatives, and through investigation compound DX-9065a (1) [10] [11] [12] [13] [14] was found to be a selective FXa inhibitor. Further, a compound YM-60828 (2) [15] [16] [17] [18] [19] [20] which is closely related to 1 in terms of structure was found to have a more potent inhibitory effect on FXa.
A characteristic common to compounds 1 and 2 is having two amidino groups in their molecules, and is considered the presence of more than one such strongly basic group is seen as an unfavorable element for adequate oral absorption and the good pharmacokinetics necessary for oral antithrombotic agents.
Based on these considerations, a compound (3) recently reported by ZENECA Co. 21) is of great interest in the following points:
i) The pK a value of 4-(piperidino)pyridine is about 12 and is nearly equal to that of amidinonaphthalene.
ii) The basicity of two nitrogen atoms in the piperazine ring is reduced by the adjacent acyl and sulfonyl groups.
iii) Due to a resonance structure of 4-dialkylaminopyridines, a 4-(piperidino)pyridine moiety in compound 3 is thought to have a plane structure as well as the naphthalene moiety in compounds 1 and 2.
To analyze the role of the carbonyl group in compound 3, the following compounds were synthesized and the inhibitory activity of FXa in vitro was evaluated in our laboratory.
In compound 4 the carbonyl group is removed and in compounds 5 and 6 the carbonyl group is replaced by a methylene group. In the present paper we wish to report the process of the above investigation.
Chemistry
Synthesis of compounds 4 and 5 was achieved as shown in Chart 1. Compound 9, prepared by the reaction of 4-piperidinone monohydrate hydrochloride (8) with (1E)-2-(4-chlorophenyl) ethenesulfonyl chloride (7) under basic conditions, was treated with 1-(4-pyridinyl)piperazine (10) in methylene chloride (CH 2 Cl 2 ) in the presence of sodium triacetoxy borohydride (NaBH(OAc) 3 ) to give desired compound 4. 22) A similar reaction was adapted to the synthesis of compound 5. Namely, 4-piperidinemethanol (11) was converted to compound (12) by treatment with compound 7 and Swern oxidation 23) of compound 12 afforded the corresponding aldehyde which condensed with compound 10 to give the desired compound 5 in satisfactory yield.
Synthesis of compound 6 and related sulfonamide derivatives (19a-l) was shown in Chart 2.
Swern oxidation of 1-(4-pyridinyl)-4-piperidinemethanol (13) which was obtained by the reaction of compound 11 with 4-chloropyridine gave the key intermediate carbaldehyde (14) . Since the aldehyde tended to form a hydrate, the crude 14 was treated with 1-piperazinecarboxylic acid 1,1-dimethylethyl ester (15) under reductive conditions to give compound 16. Deprotection of compound 16 in diethyl ether in the presence of trifluoroacetic acid (TFA) and anisole yielded compound 17, and the final compounds 6 and 19a-l were obtained smoothly by the condensation with 7 or the aromatic sulfonyl chlorides 18a-l in a similar manner to that described in the synthesis of compounds 9 and 12.
Synthesis of piperazine derivatives containing a carbon functional group at the 2-position of the piperazine ring was accomplished according to the route shown in Chart 3.
Compound 21 was easily prepared by sulfonylation of 1-(phenylmethyl)-2-piperazinecarboxylic acid ethyl ester (20) with 6-chloro-2-naphthalenesulfonyl chloride (18f) under traditional conditions. Debenzylation of compound 21 with 1-chloroethyl chloroformate afforded compound 22, and one of the desired compounds (23a) was obtained by subsequent reductive amination of compound 22 with the aldehyde 14. Then, as shown in Chart 3, the conversion of compound 23a to various derivatives (23b-g) was carried out. For example, compound 23f was obtained by coupling reaction of compound 23c with potassium ethyl malonate in the presence of carbonyl diimidazole at room temperature and the resulting mixture was heated to finish decarboxylation. Hydrolysis of compound 23f in diluted hydrochloric acid gave the corresponding acetyl compound (23g).
Finally, synthesis of the corresponding 2-piperazinone derivatives (30a-e) was carried out as shown in Chart 4.
When the aldehyde 14 was treated with N-(tert-butoxycarbonyl)-1,2-diaminoethane in the presence of NaBH(OAc) 3 in acetic acid (AcOH), a normal reductive amination product (24) was formed together with a considerable amount of a boron complex (25) in a ratio of about 1 : 2. The acylation of 24 with bromoacetyl chloride under basic conditions failed to give the desired bromoacetamido derivative (26) . In contrast, the reaction of the boron complex (25) under similar conditions afforded the bromoacetamido derivative (27) in good yield, although the reason for these phenomena is not well understood. Deprotection of compound 27 with TFA and anisole was accompanied with removal of the boron moiety to give compound 28, which smoothly cyclized into the desired 2-piperazinone (29) under basic conditions. Compounds 30a-e were obtained by sulfonation of compound 29 with several substituted naphthalenesulfonyl chlorides in yields ranging from 13 to 31%.
Results and Discussion
In comparison with compound 3, the FXa inhibitory activity of compound 4 is remarkably low, while the activity of compounds 5 and 6 is slightly less than that of compound 3 (Table 1 ). This fact seems to suggest that the whole molecular length is an important factor for the appearance of inhibitory activity of FXa and that the interaction of FXa with the carbonyl group in compound 3 is not strong. Further, compound 6 is 2 fold more active than compound 5, which means piperidine moiety is rather more favorable than piperazine moiety by the side of pyridine.
On the basis of this hypothesis, we decided to select compound 6 as the lead substance to search for a more powerful FXa inhibitor by optimization of the compound.
Next, the appropriateness of arylsulfonyl group on compound 6 was investigated, because the bulkiness and co-planarity of this group in the molecule is believed to be another important factor of the interaction between tested compounds and FXa. Among the compounds (19a-e) tested, naphthalene-2-sulfonic acid (19b) and benzo[b]thiophene-2-sulfonic acid (19d) derivatives were the most powerful inhibitors of FXa, although all the compounds showed impaired activity compared to compound 6. In addition, compound 19e, the aza-analogue of compound 19d, ran counter to our expectation, probably due to the basicity of the nitrogen atom in a thiazole ring.
Then, according to the data shown in Table 2 , the substituent effect of naphthyl and benzothienyl groups to the activity was tested. The activity of compounds 19f-l together with that of compound 6 is summarized in Table 3 .
Finally, the structure-activity relationships (SARs) studies focused on the substitution to the 2-position of the piperazine ring in compound 19f were carried out as follows. Based on the results listed in Tables 1-3 , for further development it may be desirable to restrict the mobility of the lone pair on the N1 in the piperazine ring by the electron withdrawing effect of an appropriate neighboring group. Thus, the compounds containing an electron withdrawing substituent at the 2-position of the piperazine moiety (23a-g) were evaluated for their FXa inhibitory activity. As listed in Table 4 , except for the ethoxycarbonyl group (23a), substituents at the 2-position have almost no effect on improvement of the activity. However, it should be emphasized that the introduction of a carbonyl group instead of substituents was found to be the most effective (30a), and compound 30a is about 13 times more effective than compound 6. This finding suggests that extinguishing the basicity of N1 is a very important factor for exhibition of FXa inhibitor.
In connection with this finding, replacement of the chloro substituent on the naphthalene ring of compound 30a to other substituents was investigated to prevent overlooking better compounds, but as shown in Table 5 no compound better than compound 30a could be found.
Conclusion
As described in this paper, through the modification of piperazine derivatives, we accomplished a very active com- pound (30a-M55113) as FXa inhibitor using in vitro assay. It should further be mentioned that M55113 showed clear selectivity for FXa over related serine proteases: in particular, the compound is 3000 fold more selective for FXa than for thrombin, as shown in Table 6 .
Crystallization of a complex of M55113 with FXa has already been achieved in our laboratory, so the results of crystal elucidation by X-ray analysis will be published in the near future.
Experimental
Nuclear magnetic resonance (NMR) spectra were taken with JEOL JNM-EX270 FT-NMR (JEOL, Ltd.) or JEOL JNM-LA300 (JEOL, Ltd.) in CDCl 3 or dimethyl sulfoxide-d 6 (DMSO-d 6 ) using tetramethylsilane as the internal reference. Data measured by JEOL JNM-LA300 are marked with an asterisk. The following abbreviations were used: sϭsinglet, dϭdoublet, ddϭdou-ble doublet, dtϭdouble triplet, tϭtriplet, qϭquartet, mϭmultiplet and brϭ broad. High-resolution mass spectra (HR-MS) were taken with JEOL JMS-GCMATE (JEOL, Ltd.).
Measurement of Factor Xa, Thrombin and Trypsin Inhibition The enzyme solution was mixed with a test compound dissolved at various concentrations in dimethyl sulfoxide (DMSO). Synthetic substrate was added and incubated in a 20 mM Tris-HCl buffer (pH 7.5) containing 0.13 M NaCl at 37°C. The absorbance at 405 nm was measured continuously. The following enzymes and substrates were used: human factor Xa (Enzyme Research Laboratories, Inc., 0.019 U/ml) and S-2222 (Chromogenix AB, 0.4 mM); human thrombin (Sigma Co., 0.09 U/ml) and S-2238 (Chromogenix AB, 0.2 mM); human trypsin (Athens Research and Technology, Inc., 15 ng/ml) and S-2222 (Chromogenix AB, 0.4 mM). To calculate the inhibitory activity of the test compound, the initial reaction velocity was compared with the value for a control containing no test compound. The inhibitory activity of a test compound was expressed as IC 50 .
Measurement of Anticoagulant Activity Activated partial thromboplastin time (APTT) was measured with an automatic coagulometer (KC40, Amelung Co.). Briefly, 1.5 ml of test compound diluted with DMSO at various concentrations, 50 ml of normal human plasma and 50 ml of APTT reagent (Dade Behring Inc.) were mixed and incubated for 2 min at 37°C. Then, 50 ml of 25 mM CaCl 2 solution was added to the mixture to measure clotting time. The concentration required to double the clotting time (CT2) was calculated from each individual dose-response curve (nϭ1).
1-[[(1E)-2-(4-Chlorophenyl)ethenyl]sulfonyl]-4-piperidinone (9)
Triethylamine (Et 3 N, 0.7 ml, 5 mmol) and compound 7 (1.1 g, 4.6 mmol) prepared by a documented method 21) were added to a solution of compound 8 (0.5 g, 3.7 mmol) in dry CH 2 Cl 2 (60 ml) and the mixture was stirred overnight under Ar at room temperature. Water (30 ml) was added to the reaction mixture. The mixture was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry sodium sulfate (Na 2 SO 4 ) and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent; CH 2 Cl 2 ) to give compound 9 (500 mg, 36%). 
1-[[(1E)-2-(4-Chlorophenyl)ethenyl]sulfonyl]-4-[4-(4-pyridinyl)-1-piperazinyl]piperidine (4)
AcOH (0.18 ml) was added to a solution of compound 9 (490 mg, 1.6 mmol) and compound 10 (254 mg, 1.55 mmol) prepared by a documented method 24) in dry CH 2 Cl 2 (12 ml). The mixture was stirred for 30 min under Ar at room temperature. To the stirred mixture, NaBH(OAc) 3 (660 mg, 3.1 mmol) was added and the mixture was stirred overnight at room temperature. Water (10 ml) was added to the reaction mixture. The mixture was rendered alkaline with 1 N sodium hydroxide solution and was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; CH 2 
1-[[(1E)-2-(4-Chlorophenyl)ethenyl]sulfonyl]-4-piperidinemethanol (12)
Et 3 N (0.88 ml, 6.3 mmol) and compound 7 (1.03 g, 4.3 mmol) were added to a solution of compound 11 (0.5 g, 4.3 mmol) prepared by a documented method 25) in dry CH 2 Cl 2 (10 ml) and the mixture was stirred for 4 h under Ar at room temperature. Water (10 ml) was added to the reaction mixture. The mixture was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; CH 2 Cl 2 : MeOHϭ99 : 1-97 : 3) to give compound 12 (180 mg, 13%). 
1-[[(1E)-2-(4-Chlorophenyl)ethenyl]sulfonyl]-4-[[4-(4-pyridinyl)-1-piperazinyl]methyl]piperidine (5)
A solution of oxalyl chloride (0.05 ml, 0.62 mmol) in dry CH 2 Cl 2 (1.33 ml) was cooled to Ϫ78°C under Ar. To the cooled solution, a solution of dry DMSO (0.09 ml, 1.28 mmol) in dry CH 2 Cl 2 (1.33 ml) was added dropwise over 20 min. Then, a solution of compound 12 (150 mg, 0.47 mmol) in dry CH 2 Cl 2 (1.33 ml) was added dropwise over 20 min. The reaction mixture was stirred for 1 h at between Ϫ65°C and Ϫ60°C. Then the mixture was cooled to Ϫ78°C and Et 3 N (0.25 ml, 1.8 mmol) was added. The reaction mixture was allowed to stand at room temperature. Water (2 ml) was added and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The resulting residue was suspended in dry CH 2 Cl 2 (2.0 ml) and compound 10 (42 mg, 0.25 mmol) and AcOH (0.02 ml) were added in that order. The mixture was The concentration required to double the clotting time (CT2) was calculated from each individual dose-response curve (nϭ1). The concentration required to double the clotting time (CT2) was calculated from each individual dose-response curve (nϭ1). 2 Cl 2 (65 ml) containing AcOH (1.55 ml) was stirred at room temperature for 30 min under Ar, NaBH(OAc) 3 (6.61 g, 31 mmol) was added and the mixture was stirred overnight at room temperature. Water (30 ml) was added to the reaction mixture, which was adjusted to pH 9 and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; CH 2 9 mmol) at cooling with ice bath and the mixture was stirred overnight at room temperature under Ar. Diethyl ether (200 ml) was added to the reaction mixture and vigorous stirring followed. After standing, the supernatant was removed by decantation and another 200 ml portion of diethyl ether was added; this procedure was repeated three times. Diethyl ether (200 ml) was added to the residue and the mixture was divided into fine particles, which were filtered to give compound 17 (3.24 g, 97%). and compound 7 (15.6 mg, 0.06 mmol) were added to a suspension in CH 2 Cl 2 (1.0 ml) of compound 17 (47 mg, 0.12 mmol). The mixture was stirred overnight at room temperature under Ar. Water (2 ml) was added to the reaction mixture, the mixture was rendered alkaline with 1 N sodium hydroxide solution and was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; CH 2 compound 19a (15 mg, 41%) . HR-MS m/z: Calcd for C 27 
1-(2-Methylbenzothiazol-6-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]-methyl]piperazine (19e)
Using 2-methyl-6-benzothiazolesulfonyl chloride 18e (10 mg, 0.04 mmol), synthesis was performed by the synthetic method of compound 6 to give compound 19e (8 
mg, 42%). HR-MS m/z:
Calcd for C 23 
1-[(6-Chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]-methyl]piperazine (19f)
Using 6-chloro-2-naphthalenesulfonyl chloride 18f (30 mg, 0.12 mmol), synthesis was performed by the synthetic method of compound 6 to give compound 19f (7 mg, 13%). HR-MS m/z: Calcd for C 25 2H, d, Jϭ7 Hz), 1.85-1.56 (3H, m), 1.35-1.08 (2H, m) . 
1-[(6-Bromo-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]-methyl]piperazine (19g)
Using
1-[(3-Nitrobenzo

4-[(6-Chloro-2-naphthalenyl)sulfonyl]-1-(phenylmethyl)-2-piperazinecarboxylic Acid Ethyl Ester (21)
Et 3 N (6.2 ml, 45 mmol) was added to a solution in CH 2 Cl 2 (70 ml) of compound 20 (3.7 g, 15 mmol) prepared by a documented method. 27) To this was added a solution of compound 18f (4.3 g, 16 mmol) in CH 2 Cl 2 (40 ml) under cooling with ice. After stirring the reaction mixture overnight at room temperature, water (50 ml) was added and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; hexane : ethyl acetate (AcOEt)ϭ90 : 10-80 : 20) to give compound 21 (6.4g, 85%). 
4-[(6-Chloro-2-naphthalenyl)sulfonyl]-2-piperazinecarboxylic Acid Ethyl Ester (22)
To a solution in dichloroethane (70 ml) of compound 21 (6.4 g, 14 mmol), 1-chloroethyl chloroformate (3.7 ml, 34 mmol) was added and the mixture was heated under reflux for 24 h and concentrated under reduced pressure. MeOH (60 ml) was added to the residue and the reaction mixture was heated under reflux for 2 h. This mixture was concentrated under reduced pressure and the residue was neutralized with 1 N sodium hydroxide solution and extracted with AcOEt. The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; hexane : AcOEtϭ67 : 33 and AcOEt : Et3Nϭ99.9 : 0.1) to give compound 22 (4.1 g, 79%) . 
4-[(6-Chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]-methyl]-2-piperazinecarboxylic Acid Ethyl Ester (23a)
A crude product 14 obtained by Swern oxidation using compound 13 (2.0 g, 10 mmol) was suspended in dry CH 2 Cl 2 (20 ml). To the suspension, a solution in dry CH 2 Cl 2 (30 ml) of compound 22 (2.0 g, 5.2 mmol) and AcOH (1.0 ml) were added in that order. After stirring the reaction mixture at room temperature for 30 min under Ar, NaBH(OAc) 3 (2.2 g, 10 mmol) was added and the mixture was stirred overnight at room temperature. The reaction mixture was poured into water (50 ml), adjusted to pH 9 and was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; CH 2 Cl 2 : MeOHϭ 98 : 2-90 : 10) to yield compound 23a (2.6 g, 45%) . HR-MS m/z: Calcd for C 28 
4-[(6-Chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]-methyl]-2-piperazinemethanol (23b)
A solution in CH 2 Cl 2 (3 ml) of compound 23a (9 mg, 0.016 mmol) was cooled to Ϫ78°C. To the cooled solution, 24 ml of diisobutyl aluminum hydride (as 1.5 M toluene solution) was added dropwise. The reaction mixture was stirred to room temperature, saturated ammonium chloride was added and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; CH 2 Cl 2 : MeOHϭ 95 : 5) to give compound 23b (3 mg, 30%). 
4-[(6-Chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinecarboxamide (23d)
To a solution in dry dimethylformamide (0.5 ml) of compound 23c (50 mg, 0.09 mmol), 4-dimethylaminopyridine (in a catalytic amount) and carbonyl diimidazole (17 mg, 0.1 mmol) were added in that order and the mixture was stirred at room temperature for 1 h. The reaction mixture was poured into 27% aqueous ammonia (1 ml) and stirred at room temperature for 2 h. The reaction mixture was extracted with AcOEt and the organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was crystallized with diethyl ether to give compound 23d (21 mg, 42%). HR-MS m/z: Calcd for C 26 
4-[(6-Chloro-2-naphthalenyl)sulfonyl]-N,N-dimethyl-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinecarboxamide (23e)
To a solution in dry dimethylformamide (0.5 ml) of compound 23c (50 mg, 0.09 mmol), 4-dimethylaminopyridine (in a catalytic amount) and carbonyl diimidazole (17 mg, 0.1 mmol) were added in that order and the mixture was stirred at room temperature for 1 h. The reaction mixture was poured into 50% dimethylamine solution (1 ml) and stirred at room temperature for 2 h. The reaction mixture was extracted with AcOEt and the organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was crystallized with diethyl ether to give compound 23e (21 mg, 40%). HR-MS m/z: Calcd for C 28 (0.5 ml) for 2 h was added and the resulting mixture was stirred at room temperature for 2 h, then at 40-60°C for 3 h. To the reaction mixture, 1 N HCl was added until a pH of 2 was reached. After stirring for 10 min, the mixture was neutralized with saturated sodium hydrogen carbonate and was extracted with AcOEt. The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure to give compound 23f (40 mg, 76% A crude product obtained from compound 14 (3.0 g, 15.7 mmol) by Swern oxidation was suspended in dry CH 2 Cl 2 (13 ml). To the suspension, N-(tert-butoxycarbonyl)-1,2-diaminoethane (0.54 g, 3.2 mmol) and AcOH (0.31 ml) were added in that order. After stirring the resulting mixture at room temperature for 30 min under Ar, NaBH(OAc) 3 (1.33 g, 6.3 mmol) was added and the mixture was stirred overnight at room temperature. Water (10 ml) was added to the reaction mixture, the mixture was adjusted to pH 9 with 1 N sodium hydroxide solution, and was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 28) Et 3 N (0.28 ml, 2.0 mmol) was added to a solution in dry CH 2 Cl 2 (5 ml) of a portion of compound 25 (0.6 g, 1.25 mmol). To the mixture, a solution of bromoacetyl chloride (0.31 g, 2.0 mmol) in dry CH 2 Cl 2 (5 ml) was added dropwise under cooling with ice water and the mixture was stirred at room temperature for 2 h under Ar. Ice water (10 ml) was added to the reaction mixture and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was isolated by silica gel column chromatography (eluents; CH 2 Cl 2 : MeOHϭ99 : 1) to give compound 27 (0.61 g, 81%). ) and TFA (2.3 ml) were added under cooling with ice water and the mixture was stirred at room temperature for 1.5 h under Ar. Diethyl ether (50 ml) was added and the reaction mixture was stirred vigorously. After standing, the supernatant was removed by decantation and another 50 ml of diethyl ether was added; this procedure was repeated three times. Diethyl ether (50 ml) was added to the residue and the mixture was divided into fine particles, which were filtered to give compound 28 (0.58 g, 93%). 
1-[[1-(4-Pyridinyl)-4-piperidinyl]methyl]piperazinone (29)
To a solution in dry dimethylformamide (20 ml) of a portion of compound 28 (0.46 g, 0.65 mmol), Et 3 N (1.43 ml, 10 mmol) was added under cooling with ice water; the mixture was stirred at the same temperature for 1 h, then at room temperature for another 1 h. The solvent was evaporated under reduced pressure and the residue was used in the next reaction without purification. HR-MS m/z: Calcd for C 15 94 (1H, m), 1.90-1.72 (2H, m), 1.42-1.24 (2H, m) .
4-[(6-Chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]-methyl]piperazinone (30a)
The crude product of compound 29 was suspended in dry CH 2 Cl 2 (34 ml), to the suspension, Et 3 N (0.72 ml, 5.2 mmol) and a solution of 6-chloro-2-naphthalensulfonyl chloride (245 mg, 0.94 mmol) in dry CH 2 Cl 2 (5 ml) were added in that order, and the mixture was stirred overnight at room temperature under Ar. Water (30 ml) was added to the reaction mixture, which was adjusted to pH 9 with 1 N sodium hydroxide solution and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with water and brine, dried over dry Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluents; CH 2 
